<?xml version="1.0" encoding="UTF-8"?><feed xmlns="http://www.w3.org/2005/Atom">
  <title>生物制药小编 | wechat-feeds</title>
  <id>https://github.com/hellodword/wechat-feeds</id>
  <updated>2020-12-25T11:36:46+08:00</updated>
  <subtitle>“新起点，再出发”——生物医药小编与您共同关注生物制药行业热点。</subtitle>
  <link href="https://github.com/hellodword/wechat-feeds"></link>
  <author>
    <name>hellodword</name>
  </author>
  <entry>
    <title>Bio-Empower智驱未来 | 赋能生物，开启产业数字化蓝图</title>
    <updated>2020-12-25T06:42:07+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-25:/s/65yncbDAEHvG3fW2GGJvLQ</id>
    <link href="https://mp.weixin.qq.com/s/65yncbDAEHvG3fW2GGJvLQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>4 亿大单背后：赛多利斯与荣昌的二十年</title>
    <updated>2020-12-25T06:42:07+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-25:/s/m7zUDYIZjc1J39JONVeCHw</id>
    <link href="https://mp.weixin.qq.com/s/m7zUDYIZjc1J39JONVeCHw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>IRAK4：自身免疫性疾病和肿瘤免疫双料靶点</title>
    <updated>2020-12-24T09:32:08+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-24:/s/sxxkP6b4Gc4BTLACqhO-_Q</id>
    <link href="https://mp.weixin.qq.com/s/sxxkP6b4Gc4BTLACqhO-_Q" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>康日百奥顺利取得《药品生产许可证》</title>
    <updated>2020-12-22T20:10:19+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-22:/s/smOid2YREVPyoNb3Zg5OBQ</id>
    <link href="https://mp.weixin.qq.com/s/smOid2YREVPyoNb3Zg5OBQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>抗体内化的实时动态分析及筛选—生物药物发现抗体选择和优化的关键要求</title>
    <updated>2020-12-22T20:10:19+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-22:/s/cdxKD2ZUqq9p4gRQTRjnYg</id>
    <link href="https://mp.weixin.qq.com/s/cdxKD2ZUqq9p4gRQTRjnYg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>另一种“生物导弹”→ABC</title>
    <updated>2020-12-22T20:10:19+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-22:/s/Tgh-C-dqAWSyeLW6191UVw</id>
    <link href="https://mp.weixin.qq.com/s/Tgh-C-dqAWSyeLW6191UVw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>蛋白质降解新技术: 除了火热的PROTAC，还有LYTAC，AUTAC，ATTEC</title>
    <updated>2020-12-21T18:03:13+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-21:/s/tiWy5ZCOBJzG85aXvc1LyA</id>
    <link href="https://mp.weixin.qq.com/s/tiWy5ZCOBJzG85aXvc1LyA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>分子互作研发利器SPR技术-药典指定亲和力测定技术</title>
    <updated>2020-12-21T18:03:13+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-21:/s/imTg6tYNVVWgQ-qEIFXj6w</id>
    <link href="https://mp.weixin.qq.com/s/imTg6tYNVVWgQ-qEIFXj6w" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>游方和尚专栏 | 药代动力学的重要概念和方法（二_上）：药物的血浆末端半衰期</title>
    <updated>2020-12-20T12:36:02+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-20:/s/D-esK3KngrwVxNJm4Y3pNg</id>
    <link href="https://mp.weixin.qq.com/s/D-esK3KngrwVxNJm4Y3pNg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>2020年FDA批准上市的抗癌新药/适应症</title>
    <updated>2020-12-20T12:36:02+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-20:/s/JNi5WGSJvBrRGzFV7Mjf3A</id>
    <link href="https://mp.weixin.qq.com/s/JNi5WGSJvBrRGzFV7Mjf3A" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>c-Met靶点收获之际——盘点多类型药物的开发现状</title>
    <updated>2020-12-19T10:18:18+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-19:/s/UJT4IyAMpw4wYULU1AvsUw</id>
    <link href="https://mp.weixin.qq.com/s/UJT4IyAMpw4wYULU1AvsUw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>Roche 新型CD25抗体选择性清除调节性T细胞，增强抗肿瘤免疫</title>
    <updated>2020-12-18T17:32:26+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-18:/s/4mQStGjfFcLrKi1ZqukAXQ</id>
    <link href="https://mp.weixin.qq.com/s/4mQStGjfFcLrKi1ZqukAXQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>GITR激动剂单药尽数惨败，MEDI1873停止临床研究！</title>
    <updated>2020-12-18T17:32:26+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-18:/s/YhgKSogJ4kp4Msd5-OYUaQ</id>
    <link href="https://mp.weixin.qq.com/s/YhgKSogJ4kp4Msd5-OYUaQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>CAR-Stem Cell：当CAR遇上Stem Cell</title>
    <updated>2020-12-17T19:32:23+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-17:/s/as9nie2qs2rs3ctUaW84Eg</id>
    <link href="https://mp.weixin.qq.com/s/as9nie2qs2rs3ctUaW84Eg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>重磅！NMPA正式受理HLX01（利妥昔单抗）类风湿关节炎新适应症的上市注册申请</title>
    <updated>2020-12-17T19:32:23+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-17:/s/OSZ7feknxBZR2IW7lO1AQw</id>
    <link href="https://mp.weixin.qq.com/s/OSZ7feknxBZR2IW7lO1AQw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>洞悉需求，乘势而上，以创新助力生物药生产 | 专访登山者Eppendorf</title>
    <updated>2020-12-16T21:49:17+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-16:/s/KaWZHfhQ_8Qiu0RSSYAn3A</id>
    <link href="https://mp.weixin.qq.com/s/KaWZHfhQ_8Qiu0RSSYAn3A" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>靶向双重肿瘤抗原（TAA）的双特异性抗体(BsAb)</title>
    <updated>2020-12-15T19:41:13+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-15:/s/a1EDmolt1FHftl4SXVaDlg</id>
    <link href="https://mp.weixin.qq.com/s/a1EDmolt1FHftl4SXVaDlg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
</feed>